Moneycontrol PRO
Upcoming Event:Attend Algo Convention Live, 2 Days & 12+ Speakers at best offer Rs.999/-, exclusive for Moneycontrol Pro subscribers. Register now!

Sun Pharma Q3 profit rises 11% on year to Rs 2,058.80 crore

Operating EBITDA margin declined sharply to 17.12% in the quarter from 20.43% a quarter ago and 20.97% a year ago.

January 31, 2022 / 02:17 PM IST
Analysts are positive on the growth prospect of Sun Pharma's speciality portfolio aided by Winlevi launch despite sectoral headwinds in key markets.

Analysts are positive on the growth prospect of Sun Pharma's speciality portfolio aided by Winlevi launch despite sectoral headwinds in key markets.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sun Pharmaceutical Industries Ltd on January 31 reported an 11% rise in its consolidated net profit to Rs 2,058.80 crore in the December quarter. The firm reported a profit of Rs 1,852.50 crore last year in the same quarter.

Consolidated net sales for the quarter increased 11.41% from a year ago to Rs 9,814.17 crore. Total cost advanced 12% to Rs 7,829.38 crore. Operating EBITDA margin declined sharply to 17.12% in the quarter from 20.43% a quarter ago and 20.97% a year ago.

At 2.07pm, Sun Pharma stock fell 0.47% to Rs 823 a share on the BSE.

(This is developing story and addition will be done soon)



Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

Moneycontrol Research
first published: Jan 31, 2022 02:17 pm
Sections
ISO 27001 - BSI Assurance Mark